DMAC Stock Analysis: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$6.32
-0.21 (-3.22%)
▼
5d:
+2.27%
30d:
+2.27%
90d:
-22.36%
BUY
HIGH Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 19, 2026
9d
Smart Money Accumulation
DMAC is down 4.6% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 5 OI. Call ratio: 100% View Scanner →
Strength: 7.3/10
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DMAC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: DMAC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $6.32, which is considered fair relative to its 30-day fair value range of $6.16 to $6.61.
Technical Outlook: Technically, DMAC is in a strong downtrend. Immediate support is located at $5.81, while resistance sits at $6.61. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: DMAC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+145.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DMAC is in a strong downtrend. Immediate support is located at $5.81, while resistance sits at $6.61. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: DMAC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+145.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$6.16 -
$6.61
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 145.3% below Wall St target ($15.50)
Trading Range Analysis
30-Day Trading Range
$6.16 -
$6.61
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.95
(15.0%)
Support & Resistance Levels
Support Level
$5.81
Resistance Level
$6.61
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.56
Wall Street Target
$15.50
(+145.3%)
Share & Embed Analysis
Last updated: May 08, 2026 8:42 PM ET
Data refreshes hourly during market hours. Next update: 9:42 PM
Data refreshes hourly during market hours. Next update: 9:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jan Stahlberg
BUY
73099 shares
2025-11-25
Jan Stahlberg
BUY
40253 shares
2025-11-24
Jan Stahlberg
BUY
208872 shares
2025-11-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 60 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 54 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 60 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 57 HOLD |
